Abstracts tagged "patient-reported outcome measures and psoriatic arthritis"

Abstract Number: 632 • 2018 ACR/ARHP Annual Meeting
Interpretation of Symptoms Should Take into Account Gender in Psoriatic Arthritis: An Analysis of 451 Patients
Clémence Gorlier¹, Laure Gossec², Deborah Puyraimond-Zemmour¹, Laura C. Coates³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder¹⁵, Inna Gaydukova¹⁶, Ennio Lubrano¹⁷, Pascal Richette¹⁸, M. Elaine Husni¹⁹, Maarten de Wit²⁰, Josef S. Smolen²¹ and Ana-Maria Orbai²², ¹Sorbonne Université, PARIS, France, ²Rhumatologie, Médecine Sorbonne Université, Pitié-Salpétrière Hospital, Paris, France, ³University of Oxford, Oxford, United Kingdom, ⁴Rheumatology, Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁷Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁸Rheumatology, Université Paris Diderot, Paris, France, ¹⁹Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²⁰Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Treatments targets in psoriatic arthritis (PsA) are remission (REM) or Low Disease Activity (LDA) which are usually defined based on objective disease activity but…
Abstract Number: 965 • 2018 ACR/ARHP Annual Meeting
Defining Cutoffs Corresponding to Low Levels of Disease Activity in Psoriatic Arthritis, Using the Patient-Reported Psoriatic Arthritis Impact of Disease Questionnaire (PsAID12). an Analysis of 436 Patients
Clémence Gorlier¹, Deborah Puyraimond-Zemmour¹, Ana-Maria Orbai², Laura C. Coates³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder^15,16, Inna Gaydukova¹⁷, Ennio Lubrano¹⁸, Pascal Richette¹⁹, M. Elaine Husni²⁰, Maarten de Wit²¹, Josef S. Smolen²² and Laure Gossec²³, ¹Sorbonne Université, PARIS, France, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Oxford, Oxford, United Kingdom, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ¹⁷North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁸Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁹Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ²⁰Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²¹Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²²Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²³Rhumatologie, Médecine Sorbonne Université, Pitié-Salpétrière Hospital, Paris, France
Background/Purpose: The Psoriatic Arthritis (PsA) Impact of Disease questionnaire (PsAID12) score allows an assessment of patient-important symptoms and life impact in PsA. It is provisionally…
Abstract Number: 1638 • 2018 ACR/ARHP Annual Meeting
Impact of Extra-Articular Manifestations on Patient-Reported Outcomes in Ankylosing Spondylitis and Psoriatic Arthritis: Interim Results from the Complete Studies
Louis Bessette¹, Majed Khraishi^2,3, Brandusa Florica⁴, Yatish Setty⁵, Michelle Teo⁶ and Valencia P. Remple⁷, ¹Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ²Memorial University of Newfoundland, St. John's, NF, Canada, ³Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Grey Bruce Health Services, Owen Sound, ON, Canada, ⁶University of British Columbia, Penticton, BC, Canada, ⁷AbbVie Corporation, Montreal, QC, Canada
Background/Purpose: Extra-articular manifestations (EAMs) in rheumatic diseases have been previously found to negatively impact health outcomes including quality of life and work capacity. Even though…
Abstract Number: 2914 • 2018 ACR/ARHP Annual Meeting
Examination of Psychometric Properties of the Patient-Reported Outcomes Measurement Information System Fatigue 4-Item Short Form in Psoriatic Arthritis
Patricia Katz^1,2, Alexis Ogdie³, Evo Alemao⁴, Jayanti Mukherjee⁴ and Kaleb Michaud^2,5, ¹Forward/National Data Bank for Rheumatic Diseases, Wichita, KS, ²University of California San Francisco, San Francisco, CA, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: PROMIS (Patient-Reported Outcomes Measurement Information System) measures have not been tested in psoriatic arthritis (PsA). We examined the reliability, validity and responsiveness of the…
Abstract Number: 595 • 2017 ACR/ARHP Annual Meeting
Improved Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Abatacept: Results from a Phase III Trial
Vibeke Strand¹, E Alemao², T Lehman², A Johnsen², S Banerjee², HA Ahmad² and Philip J Mease³, ¹Stanford University, Palo Alto, CA, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: In the Phase III ASTRAEA study (NCT01860976), abatacept (ABA) significantly increased ACR20 responses, alleviating musculoskeletal symptoms in patients (pts) with active psoriatic arthritis (PsA).1…
Abstract Number: 2730 • 2016 ACR/ARHP Annual Meeting
Impact of Disease Flare Perception on Work Productivity and Treatment Satisfaction in Patients with Psoriatic Arthritis in Real World Setting
William Tillett^1,2, James Piercy³, Su Chen⁴ and Fabiana Ganz⁵, ¹Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Adelphi Real World, Cheshire, United Kingdom, ⁴AbbVie, North Chicago, IL, ⁵Neuhofstrasse 23, AbbVie, Baar, Switzerland
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) may experience temporary worsening of symptoms or disease flare, which can be painful enough to interfere with day-to-day…
Abstract Number: 3186 • 2016 ACR/ARHP Annual Meeting
Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis and Levels of Discordance According to Disease Activity: A Multicenter European Study
Carole Desthieux¹, Benjamin Granger², Andra Rodica Balanescu³, P Balint⁴, Jürgen Braun⁵, Juan Canete⁶, Turid Heiberg⁷, Philip S. Helliwell⁸, Umut Kalyoncu⁹, Tore K Kvien¹⁰, Uta Kiltz⁵, Dora Niedermayer¹¹, Kati Otsa¹², Rossana Scrivo¹³, Josef Smolen¹⁴, Tanja A. Stamm¹⁵, Douglas J. Veale¹⁶, Kurt de Vlam¹⁷, Maarten de Wit¹⁸ and Laure Gossec¹, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Biostatistics, Pitié Salpêtrière Hospital, Paris, France, ³Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ⁴Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Rheumatology, Hospital Clínic and IDIBAPS, Barcelona, Spain, ⁷Oslo University Hospital, Oslo, Norway, ⁸NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁹Hacettepe University, Ankara, Turkey, ¹⁰Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹¹PsAID taskforce, EULAR, Zurich, Switzerland, ¹²Rheumatology, Tallinn Central Hospital, Tallinn, EE, ¹³Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ¹⁴Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹⁵Internal Medicine III, Vienna Medical University, Vienna, Austria, ¹⁶Consultant Rheumatologist, Centre for Arthritis and Rheumatic Disease, St. Vincent’s University Hospital and University College Dublin, Dublin 4, Ireland, ¹⁷Katholieke Universiteit Leuven, Leuven, Belgium, ¹⁸Medical Humanities, VU Medical Centre, Amsterdam, Netherlands
Background/Purpose: In the management of chronic diseases, recommendations insist on the need to work in partnership with the patient. Patient-physician discordance in global assessment of…
Abstract Number: 1554 • 2013 ACR/ARHP Annual Meeting
Real-World Effectiveness Of Infliximab In The Treatment Of Psoriatic Arthritis Over 12 Months: The Canadian Experience
Proton Rahman¹, Majed M. Khraishi², William Bensen³, John T. Kelsall⁴, Brian D. Hanna⁵, Craig Watts⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, May Shawi⁸, Susan M. Otawa⁹ and Allen J. Lehman⁹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Nexus Clinical Research, St John's, NF, Canada, ³St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Rheumatology, McMaster University, Ontario, Kitchener, ON, Canada, ⁶Department of Rheumatology, McGill University and Montreal General Hospital, Sainte-Anne-de-Bellevue, QC, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].